Anti-FOXL2 抗体 (ab5096)
Key features and details
- Goat polyclonal to FOXL2
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-FOXL2 antibody
FOXL2 一次抗体 製品一覧 -
製品の詳細
Goat polyclonal to FOXL2 -
由来種
Goat -
アプリケーション
適用あり: WBmore details -
種交差性
交差種: Human
交差が予測される動物種: Mouse, Rat, Cow
-
免疫原
Synthetic peptide corresponding to FOXL2 aa 364-376 (C terminal).
Sequence:DSKTGALHSRLDL
-
ポジティブ･コントロール
- WB: K562 and HeLa cell lysates.
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
バッファー
pH: 7.30
Preservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 0.5% BSA -
Concentration information loading... -
精製度
Immunogen affinity purified -
特記事項（精製）
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab5096の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| WB | (2) |
Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 45-50 kDa (predicted molecular weight: 43 kDa).
Primary incubation 1 hour at room temperature. |
| 特記事項 |
|---|
|
WB
Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 45-50 kDa (predicted molecular weight: 43 kDa). Primary incubation 1 hour at room temperature. |
ターゲット情報
-
機能
Transcriptional regulator. Critical factor essential for ovary differentiation and maintenance, and repression of the genetic program for somatic testis determination. Prevents trans-differentiation of ovary to testis throught transcriptional repression of the Sertoli cell-promoting gene SOX9 (By similarity). Has apoptotic activity in ovarian cells. Suppresses ESR1-mediated transcription of PTGS2/COX2 stimulated by tamoxifen (By similarity). Is a regulator of CYP19 expression (By similarity). Participates in SMAD3-dependent transcription of FST via the intronic SMAD-binding element (By similarity). Is a transcriptional repressor of STAR. Activates SIRT1 transcription under cellular stress conditions. Activates transcription of OSR2. -
組織特異性
In addition to its expression in the developing eyelid, it is transcribed very early in somatic cells of the developing gonad (before sex determination) and its expression persists in the follicular cells of the adult ovary. -
関連疾患
Defects in FOXL2 are a cause of blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) [MIM:110100]; also known as blepharophimosis syndrome. It is an autosomal dominant disorder characterized by eyelid dysplasia, small palpebral fissures, drooping eyelids and a skin fold running inward and upward from the lower lid. In type I BPSE (BPES1) eyelid abnormalities are associated with female infertility. Affected females show an ovarian deficit due to primary amenorrhea or to premature ovarian failure (POF). In type II BPSE (BPES2) affected individuals show only the eyelid defects. There is a mutational hotspot in the region coding for the poly-Ala domain, since 30% of all mutations in the ORF lead to poly-Ala expansions, resulting mainly in BPES type II.
Defects in FOXL2 are a cause of premature ovarian failure type 3 (POF3) [MIM:608996]. An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. -
配列類似性
Contains 1 fork-head DNA-binding domain. -
翻訳後修飾
Sumoylated by SUMO1; sumoylation is required for transcriptional repression activity. -
細胞内局在
Nucleus. - Information by UniProt
-
参照データベース
- Entrez Gene: 281770 Cow
- Entrez Gene: 668 Human
- Entrez Gene: 26927 Mouse
- Entrez Gene: 367152 Rat
- Omim: 605597 Human
- SwissProt: Q6VFT7 Cow
- SwissProt: P58012 Human
- SwissProt: O88470 Mouse
see all -
別名
- Blepharophimosis antibody
- Blepharophimosis epicanthus inversus and ptosis 1 antibody
- Blepharophimosis epicanthus inversus and ptosis antibody
see all
画像
-
Western blot - Anti-FOXL2 antibody (ab5096)All lanes : Anti-FOXL2 antibody (ab5096) at 2 µg/ml
Lane 1 : K562 cell lysate, 35µg protein in RIPA buffer
Lanes 2 & 4 : K562 cell lysate incubated with immunizing peptide, 35µg protein in RIPA buffer
Lane 3 : HeLa cell lysate, 35µg protein in RIPA buffer
Developed using the ECL technique.
Predicted band size: 43 kDa
Observed band size: 35 kDa why is the actual band size different from the predicted?Primary incubation 1 hour at room temperature.
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (49)
ab5096 は 49 報の論文で使用されています。
- Heng D et al. Mtor inhibition by INK128 extends functions of the ovary reconstituted from germline stem cells in aging and premature aging mice. Aging Cell 20:e13304 (2021). PubMed: 33448083
- Frost ER et al. Two alternative methods for the retrieval of somatic cell populations from the mouse ovary. Mol Hum Reprod 27:N/A (2021). PubMed: 33973015
- Habara O et al. WNT signaling in pre-granulosa cells is required for ovarian folliculogenesis and female fertility. Development 148:N/A (2021). PubMed: 33914868
- Li R et al. Increased FOXL2 expression alters uterine structures and functions†. Biol Reprod 103:951-965 (2020). PubMed: 32948877
- Pierini S et al. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. JCI Insight 5:N/A (2020). PubMed: 32814714